Also listed on GlaxoSmithKline Intellectual Property Development Limited, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends May 19, 2036 · High confidence
20-year base term ends May 19, 2036
May 19, 2016
May 19, 2036
Apr 4, 2023
This patent's term runs 206 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 19, 2016, when application 15/158,858, the earliest non-provisional in its chain, was filed (this one was filed Nov 9, 2017) | May 19, 2036 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +206 days, USPTO patent term adjustment record | Dec 11, 2036 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,195,160, US 11,458,108, US 11,622,945) | capped to May 19, 2036 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | May 19, 2036 | High confidence |
This family
| US 10,195,160 | In force May 2036 | May 2036 |
| US 11,617,724 | this patent May 2036 | May 2036 |
| US 11,458,108 | In force May 2036 | May 2036 |
| US 11,622,945 | In force May 2036 | May 2036 |
| US 10,426,743 | In force May 2036 | May 2036 |
| US 11,612,573 | In force May 2036 | May 2036 |
| Application 18/066,945 | Pending not computed | not computed |
| Application 18/643,595 | Abandoned not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 24, 2018 Reel 46697, frame 848 | Dermavant Sciences GmbH | Novaquest Co.-Investment Fund VIII, L.P. | Security Interest |
| Mar 12, 2019 Reel 48574, frame 173 | Sonti, Sujatha D.; Lenn, Jon D.; Santos, Leandro L.; Whiteman, Justin E.; Doherty, Michael Quinn; Bedard, Mary; GlaxoSmithKline LLC; GlaxoSmithKline Research and Development Limited | GlaxoSmithKline Intellectual Property Development Limited | Assignment of Assignor's Interest |
| Mar 12, 2019 Reel 48574, frame 500 | Jain, Piyush; GlaxoSmithKline LLC; GlaxoSmithKline Research and Development Limited | GlaxoSmithKline Intellectual Property Development Limited | Assignment of Assignor's Interest |
| Mar 12, 2019 Reel 48577, frame 304 | Glaxo Group Limited; GlaxoSmithKline Intellectual Property Development Limited | Dermavant Sciences GmbH | Assignment of Assignor's Interest |
| May 24, 2019 Reel 49285, frame 377 | Dermavant Sciences GmbH | Hercules Capital, Inc., as Agent | Intellectual Property Security Agreement |
| Dec 18, 2019 Reel 51320, frame 993 | Thomas, Joey Roger; GlaxoSmithKline LLC; GlaxoSmithKline Research and Development Limited | GlaxoSmithKline Intellectual Property Development Limited | Assignment of Assignor's Interest |
| Oct 15, 2020 Reel 54070, frame 515 | Thomas, Joey Roger; GlaxoSmithKline LLC; GlaxoSmithKline Research and Development Limited | GlaxoSmithKline Intellectual Property Development Limited | Assignment of Assignor's Interest |
| May 17, 2021 Reel 56261, frame 437 | Dermavant Sciences GmbH | U.S. Bank National Association | Security Interest |
| May 19, 2021 Reel 56399, frame 778 | Dermavant Sciences GmbH | U.S. Bank National Association | Security Interest |
| Sep 3, 2024 Reel 68471, frame 692 | Hercules Capital, Inc., as Agent | Dermavant Sciences GmbH | Release of Security Interest |
| Oct 29, 2024 Reel 69274, frame 101 | US Bank Trust Company, National Association | Dermavent Sciences GmbH | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,195,160, US 11,458,108, US 11,622,945.